KRYS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRYS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Krystal Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.47 Mil. Krystal Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.62 Mil. Krystal Biotech's annualized EBITDA for the quarter that ended in Dec. 2023 was $462.80 Mil. Krystal Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.02.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Krystal Biotech's Debt-to-EBITDA or its related term are showing as below:
During the past 8 years, the highest Debt-to-EBITDA Ratio of Krystal Biotech was 0.45. The lowest was -1.62. And the median was -0.14.
The historical data trend for Krystal Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.16 | -0.38 | -0.12 | -0.07 | 0.45 |
Krystal Biotech Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.04 | -0.06 | -0.06 | -0.08 | 0.02 |
For the Biotechnology subindustry, Krystal Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Krystal Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.474 | + | 6.62) | / | 17.904 | |
= | 0.45 |
Krystal Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.474 | + | 6.62) | / | 462.8 | |
= | 0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.
Krystal Biotech (NAS:KRYS) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Krystal Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Krish S Krishnan | director, 10 percent owner, officer: President and CEO | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Suma Krishnan | director, 10 percent owner, officer: Chief Operating Officer | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Catherine Mazzacco | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Daniel Janney | director | PO BOX 7414, JACKSON WY 83002 |
Andrew C. Orth | officer: Chief Commercial Officer | 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Kathryn Romano | officer: Chief Accounting Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Dino A Rossi | director | 61 WATROO POINT, DANIEL ISLAND SC 29492 |
Everett Rand Sutherland | director | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Christopher Mason | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Jing L. Marantz | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Julian S Gangolli | director | 4955 BASELINE AVENUE, SANTA YNEZ CA 93460 |
Jennifer Chien | officer: Chief Commercial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Antony A Riley | officer: Chief Financial Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538 |
R Douglas Norby | director | C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014 |
Sun Pharma (netherlands) B.v. | 10 percent owner | POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000 |
From GuruFocus
By Value_Insider Value_Insider • 12-05-2022
By Value_Insider Value_Insider • 12-14-2022
By Value_Insider Value_Insider • 12-01-2022
By GlobeNewswire GlobeNewswire • 08-18-2022
By Marketwired • 09-05-2023
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 04-13-2023
By Stock market mentor Stock market mentor • 01-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.